drugset / Trial / NCT05827549

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

NCT05827549

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence. Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for relapsed acute lymphoblastic leukemia in children and adolescents.

Timeline

Start
2024-04-04
Primary completion
2032-12-31
Completion
2032-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Blinatumomab Monoclonal antibody 5 ug/m2
Subject Blinatumomab Monoclonal antibody 9 ug
Subject Blinatumomab Monoclonal antibody 15 ug/m2
Subject Blinatumomab Monoclonal antibody 28 ug
Subject Cytarabine Small molecule 1 g Intrathecal
Subject Cytarabine Small molecule 3000 mg/m2 Intrathecal
Subject Dexamethasone Small molecule 5 mg/m2
Subject Dexamethasone Small molecule 8 mg/m2
Subject Etoposide Small molecule 100 mg/m2
Subject Idarubicin Small molecule 5 mg/m2
Subject Idarubicin Small molecule 10 mg/m2
Subject Ifosfamide Small molecule 1.8 g
Subject Ifosfamide Small molecule 3.4 g
Subject MERCAPTOPURINE ANHYDROUS Small molecule 50 mg/m2 Oral
Subject Methotrexate Small molecule 20 mg/m2 Intrathecal
Subject Methotrexate Small molecule 25 mg/m2 Intrathecal
Subject Methotrexate Small molecule 500 mg/m2 Intrathecal
Subject Methotrexate Small molecule 1000 mg/m2 Intrathecal
Subject Prednisolone Other / unclassified 15 mg/m2
Subject Prednisolone Other / unclassified 60 mg/m2
Subject Vincristine Small molecule 1.5 mg/m2
Subject Vincristine Small molecule 2 mg/m2
Subject asparaginase Protein / enzyme biologic 6000 iu/kg
Subject asparaginase Protein / enzyme biologic 10000 iu/kg